MedTrace Logo

Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period

NCT01900834 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2016-10-10

No results posted yet for this study

Summary

This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy, non-diabetic subjects over a one year period.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Healthy

Interventions

OTHER

No treatment given

The participants will not receive any treatment

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR,1452) · Novo Nordisk A/S

Eligibility

Min Age
14 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01900834 on ClinicalTrials.gov